Introduction {#S0001}
============

Breast cancer (BC) is a severe health problem worldwide and ranked as the second cause of cancer-associated deaths in females.[@CIT0001] According to the American cancer society statistics report in 2018, there were 26612 new cases and 40920 deaths of BC.[@CIT0002] In general, BC is classified into different types by the expression level of estrogen receptor (ER), epidermal growth factor receptor (HER2), and progesterone receptor (PR). Different types of BC respond in different ways to various types of treatment, making it more challenging to develop accurate therapeutic methods and drugs that are both effective and safe to BC patients.[@CIT0003],[@CIT0004] Hence, huge efforts are required for developing more effective therapeutic agents.

A lot of natural products have been reported to have anti-cancer effects in various types of cancer.[@CIT0005],[@CIT0006] Ursolic acid (UA) ([Figure 1A](#F0001){ref-type="fig"}) is a pentacyclic triterpenoid compound extracted from naturally growing herbs, such as apples, pears, and loquat.[@CIT0007],[@CIT0008] Several studies have confirmed that UA has shown strong anticancer effects against lung cancer, BC, and so on.[@CIT0009],[@CIT0010] Yeh et al investigated that UA inhibited cancer cell invasion, migration, and proliferation in MDA-MB-231 via down-regulating u-PA and MMP-2 expression, and up-regulating the expression of PAI-I and TIMP-2.[@CIT0011] UA has also been reported to reduce the phosphorylation of AKT/mTOR signaling for modulating proliferation and apoptosis.[@CIT0012],[@CIT0013] Shishodia et al found that UA had the potential to regulate the cytokines signaling cascade by inhibiting NF-κB stimulation.[@CIT0014] While these studies provided a foundation of possible mechanisms of UA, its precise molecular anti-BC mechanisms and target molecules remain unclear.Figure 1UA construct and the effect of UA on proliferation in MCF-7 cells. (**A**) Ursolic acid construct. (**B**) The anti-growth of ursolic acid in MCF-7 cells treated with different doses of ursolic acid (0, 4, 16, 64, and 128 μM) by MTT assay at 570 nm (OD570 nm). This figure showed that the growth of MCF-7 cells was decreased by ursolic acid in a dose-dependent manner. \*\*P\<0.01, \*P\<0.05 vs untreated group.**Abbreviations:** UA, ursolic acid; MTT, methyl thiazolyl tetrazolium; OD570 nm, optical density at 570 nm.

Recently, connectivity map (CMAP) database has frequently been employed to resolve the molecular mechanisms and target prediction of drugs.[@CIT0015],[@CIT0016] Liu et al predicted novel histone deacetylase inhibitors by CMAP.[@CIT0017] Lee et al elucidated the potential molecular mechanisms of berberine through CMAP approach.[@CIT0018] Thus, CMAP-based strategies can dramatically streamline the molecular mechanisms and target molecules prediction process for drugs or potential active ingredients. The current study investigated the precise molecular mechanism of UA using CMAP approach. The results suggested that UA could inhibit PLK1, IKK/NF-κB, and RAF/ERK pathways in MCF-7. Our finding provided an extensive view of the anti-tumor mechanisms of UA.

In the present study, the potential molecular mechanisms of UA were analyzed by measuring the gene expression profiles of MCF-7 cells incubated by UA using CMAP approach. Then, the results of CMAP analysis were further verified (validated) by Western blot. Our results demonstrated that UA may inhibit PLK1, IKK/NF-κB, and RAF/ERK pathways. Our finding provided an extensive view of the anti-tumor mechanisms of UA.

Materials and Methods {#S0002}
=====================

Materials {#S0002-S2001}
---------

UA was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Human breast cancer MCF-7 cells were obtained from Shanghai Cell Bank of Chinese Academy of Science (Shanghai, China). Trizol was from Invitrogen (CA, USA). Microarray analysis was finished by Oebiotech (Shanghai, China). Specific antibodies for GAPDH, BRAF, PLK1, IKKβ, NF-κB p65, ERK1/2, p-ERK1/2, p-IKKβ, p-BRAF, p-NF-κB p65, and p-PLK1 were purchased from Abcam (Cambridge, UK).

Cell Culture {#S0002-S2002}
------------

MCF-7 cells were maintained in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100U/mL penicillin and 100mg/mL streptomycin at 37°C with a humidified atmosphere of 5% CO~2~. DMEM, FBS, and antibiotics were purchased from Gibco, Thermo Fisher Scientific, Inc. (Waltham, MA, USA).

Cell Viability Assay {#S0002-S2003}
--------------------

MCF-7 cells were inoculated in 96-well plates (10^4^/well). When cells were in the logarithmic growth period, different concentrations of UA (from 0 to 64 μM) were added. After the cells were treated for 24 h, 20 μL of MTT solution (5 mg/mL) was added to each well for another culture for 4 h at 37°C. Then, 100 μL of DMSO was added into each well for 10 min. The optical density (OD) was measured by the microplate reader at 570 nm. Each assay was performed triplicate.

RNA Extraction and Microarray Analysis {#S0002-S2004}
--------------------------------------

The Agilent SurePrint G3 Human Gene expression v3 Microarrays (8\*60K, Design ID: 072363) were used on the Agilent Microarray-Based Gene Expression Analysis platform by OEbiotech Co., Ltd. (Shanghai, P.R. China). In brief, the total RNA was extracted from MCF-7 cells treated with/without UA 20uM, and then quantified by the NanoDrop ND-2000 (Thermo Scientific) and the RNA integrity was assessed by Agilent Bioanalyzer 2100 (Agilent Technologies). The total RNA were reverse-transcribed to double-strand cDNA, then synthesized into cRNA and labeled with Cyanine-3-CTP. The labeled cRNAs were hybridized onto the microarray. After washing, the arrays were scanned by the Agilent Scanner G2505C (Agilent Technologies). The Feature Extraction software (Version10.7.1.1, Agilent Technologies) was used to analyze array images to get raw data. Genespring (Version 13.1, Agilent Technologies) was employed to finish the basic analysis with the raw data. To begin with, the raw data were normalized with the quantile algorithm. The probes that at least 1 condition out of 2 conditions has flags in "P" were chosen for further data analysis. Differentially expressed genes were then identified through fold change. The threshold set for up- and down-regulated genes was a fold change ≥ 2.0. Afterwards, GO analysis and KEGG analysis were applied to determine the roles of these differentially expressed mRNAs.

Western Blot {#S0002-S2005}
------------

MCF-7 cells, incubated with (4 and 20 μM) UA for 24 h, were washed with cold phosphate buffer, then incubated with protein extract buffer for 30 min at −80°C. The lysates were centrifuged at 15,000 × g for 40 min and protein concentration was measured by BCA kit (Tiangen, Beijing, China). Protein lysates (25 μg) from each sample were subjected to SDS-PAGE on 15% acrylamide gel and transferred to the PVDF membrane. Blots were incubated with 5% nonfat milk to block nonspecific binding sites at 4°C overnight and then incubated with antibodies against BRAF, ERK1/2, IKKβ, NF-κB p65, PLK1, phosphor-ERK1/2, phosphor-p65, phosphor-IKKβ, phosphor-PLK1 and GAPDH for 1.5 h at 37°C. Membranes were then incubated with HRP-conjugated secondary antibodies for 1 h at 37°C. Finally, membranes were detected by ECL kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA).

Molecular Docking {#S0002-S2006}
-----------------

Docking prediction was performed with iGEMDOCK software. The structures of IKKβ (4KIK), BRAF (5CSW), and PLK1 (3RQ7) were obtained from the Protein Data Bank. The 3D structure of UA was obtained from National Center for Biotechnology Information, then transformed to MOL2 format using the software of Open Babel (v. 2.4.1). The binding sites were prepared, and energy-minimized compounds were imported. The docking protocol is set to 80 generations per ligand and a population size id 300 random individuals.

Statistics Analysis {#S0002-S2007}
-------------------

Statistics analysis was performed with Origin 8.0. The data were expressed as mean±SD. Statistical analysis of the results was performed using the *t*-test for pairwise comparison. Differences were considered statistically significant at P\<0.05 (\*) or highly significant at p\<0.01 (\*\*).

Results {#S0003}
=======

UA Inhibits Cell Viability of MCF-7 Cells {#S0003-S2001}
-----------------------------------------

The inhibitory effect of UA on MCF-7 cell growth was determined by MTT assay. As shown in [Figure 1B](#F0001){ref-type="fig"}, the cell viability was decreased by UA in a dose-dependent manner. The IC50 values for UA to reduce cell viability were 20 μM ([Figure 1B](#F0001){ref-type="fig"}).

In addition, we found that 20 μM UA inhibited the growth of MCF-7 cells as early as 6 h ([[Supplementary Figure 1](https://www.dovepress.com/get_supplementary_file.php?f=241957.docx)]{.ul}). Hence, the microarray and Western blot were performed on MCF-7 cells, treated with UA for 6 h and 24 h, respectively.

Microarray and CMAP Analysis of MCF-7 Treated with UA {#S0003-S2002}
-----------------------------------------------------

MCF-7 cells, treated with 20 μM UA for 6 h, produced the initial gene expression profiles and fold change was used to filter the differential expression genes of UA ([[Supplementary Data 1](https://www.dovepress.com/get_supplementary_file.php?f=241957.docx)]{.ul}). The result showed that it contained 355 up-regulated genes and 121 down-regulated genes (both \>2-fold change, respectively). Then, the GO and KEGG pathway analyses were performed by using a multi-omics data analysis tool ([Figure 2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}).Figure 2Gene expression profile of UA anti-tumor mechanisms. (**A**) GO enrichment analysis. (**B**) KEGG enrichment analysis.**Abbreviations:** UA, ursolic acid; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

The different gene expressions triggered by UA were submitted to the connectively MAP database for analysis. As shown in [Table 1](#T0001){ref-type="table"}, the results suggested that UA exerted its anti-cancer activity through modulating RAF, PLK, IKK, and NF-κB, based on the character of BC. These findings were beneficial for exploring the anti-cancer mechanism of UA in MCF-7 cells.Table 1The CMAP Analysis of the Different Gene Expression Triggered by UARankCMAP InhibitorDescriptionScore1HU-211NFkB pathway inhibitor99.662BRD-K98824517Tyrosine phosphatase inhibitor99.513Angiogenesis-inhibitorAngiogenesis inhibitor99.074FlubendazoleTubulin inhibitor98.825AG-957Abl kinase inhibitor98.756GDC-0879RAF inhibitor98.667Withaferin-aIKK inhibitor, NFkB pathway inhibitor, PKC inhibitor98.518CladribineAdenosine deaminase inhibitor, DNA synthesis inhibitor98.379ON-01910PLK inhibitor97.8310Cyclopiazonic acidATPase inhibitor97.75[^1]

UA Down-Regulates RAF/ERK Pathway {#S0003-S2003}
---------------------------------

The CMAP results suggested that UA may act in a similar to that of RAF inhibitors. In BC, BRAF, the most important member of RAF, can activate ERK through phosphorylation to promote proliferation and invasion.[@CIT0019] Therefore, we evaluated the protein levels involved RAF/ERK pathway. As shown in [Figure 3](#F0003){ref-type="fig"}, UA treatment significantly reduced the phosphorylation levels of BRAF and ERK1/2 when compared to the untreated cells. The results suggest that UA exerts anti-BC effect via RAF/ERK pathway in MCF-7 cells.Figure 3The effect of UA on BRAF/ERK pathway in MCF-7 cells. (**A**) The expression levels of BRAF, p-BRAF, ERK1/2, and p-ERK1/2 were measured by Western blot in MCF-7 cells treated with 0 μM, 4 μM, and 20 μM UA. GAPDH was used as internal control. (**B**) The relative expression of BRAF, p-BRAF, ERK1/2, and p-ERK1/2 was analyzed by software ImageJ. \*\*P\<0.01 vs untreated group (**C**) The relative expression of ERK1/2 and p-ERK1/2 was analyzed by software ImageJ. \*\*P\<0.01, \*P\<0.05 vs untreated group.**Abbreviations:** UA, ursolic acid; BRAF, B-RAF serine/threonine kinase protein; p-BRAF, phosphorylated B-RAF serine/threonine kinase protein; ERK-extracellular regulated protein kinases; ERK1/2, extracellular regulated protein kinases 1/2; p-ERK1/2, phosphorylated extracellular regulated protein kinases 1/2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

UA Decreased the Phosphorylation Levels of PLK1 {#S0003-S2004}
-----------------------------------------------

PLK (polo-like kinase), a family of serine/threonine phosphatase, is the key mediator of cancer cell growth and proliferation.[@CIT0020] Among the PLK members, PLK1 correlates with poor prognosis as the high expression in various cancers including BC.[@CIT0021],[@CIT0022] Hence, we investigated the effect of UA on PLK1 expression in MCF-7 cells. As shown in [Figure 4](#F0004){ref-type="fig"}, the phosphorylation level of PLK1 was significantly decreased by UA. These results were coordinated with the CMAP and microarray analysis and supported the notion that UA exerts an inhibition on the PLK phosphorylation.Figure 4The effect of UA on PLK1 in MCF-7 cells. (**A**) Western blot was used to assess the levels of PLK1 and phosphor-PLK1 in MCF-7 cells treated with 0 μM, 4 μM, and 20 μM UA, respectively. GAPDH was used as internal control. (**B**) The relative expression of PLK1 and p-PLK1 was analyzed by software ImageJ. \*\*P\<0.01, vs untreated group.**Abbreviations:** UA, ursolic acid; PLK1, polo-like kinase 1; p-PLK1, phosphorylated polo-like kinase 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

UA Modulates IKK/NF-κB Pathway {#S0003-S2005}
------------------------------

The CMAP analysis indicated that UA has the similar effect on gene expression with NF-κB pathway inhibitor. In NF-κB pathway, IKKβ mediates phosphorylation of IκB/p65p50 complex. The IκB/p65p50 complex represents an inactivated cytoplasmic form of NF-κB.[@CIT0023] When IKKβ was activated, it phosphorylates the IκB/p65p50 complex, then releasing phosphorylated p65, which can interact with its DNA binding site to up-regulate the anti-apoptotic gene transcription, in cancer cells.[@CIT0024] To determine the effects of UA on the IKK/NF-κB pathway, the activation statuses of IKKβ and p65 were examined in MCF-7 cells. In [Figure 5](#F0005){ref-type="fig"}, UA treatment significantly reduced the phosphorylated levels of IKKβ and p65, without affecting total IKKβ and p65 expression. These results suggest that UA exerts an inhibition on the IKK/NF-kB pathway.Figure 5The effect of UA on IKK/NF-κB p65 pathway in MCF-7 cells. (**A**) Western blot was used to assess the levels of IKKβ, p-IKKβ, p65, and p-p65 in MCF-7 cells treated with 0 μM, 4 μM, and 20 μM UA, respectively. GAPDH was used as internal control. (**B**) The relative expression of IKKβ, phosphor-IKKβ, p65, and p-p65 was analyzed by software ImageJ. \*\*P\<0.01, \*P\<0.05 vs untreated group. (**C**) The relative expression of p65 and p-p65 was analyzed by software ImageJ. \*P\<0.05 vs untreated group.**Abbreviations:** UA, ursolic acid; IKK, inhibitor of nuclear factor kappa-B kinase; NF-κB, nuclear factor kappa-B; IKKβ, inhibitor of nuclear factor kappa-B kinase β; p-IKKβ, phosphorylated inhibitor of nuclear factor kappa-B kinase β; p65, nuclear factor kappa-B p65; p-p65, phosphorylated nuclear factor kappa-B p65; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

The Docking Analysis of UA with BRAF, IKK, and PLK1 {#S0003-S2006}
---------------------------------------------------

iGEMDOCK is an important software for molecular docking, which predicts the mode of interaction between ligand and receptor. Binding energy provides the information to us for understanding the strength and how much affinity a compound binds to the pocket of the receptor. The docking results for iGEMDOCK showed that the binding energy of UA between BRAF, ﻿IKKβ, and PLK1 were −87.6, −99.7, and −78.2kcaj/mol, respectively. As shown in [Figure 6](#F0006){ref-type="fig"}, VAL-482, LYS-483, THR-529, TRP-531, CYS-532, and PHE-583, located in functional domain, were the amino acid residues in the binding sites of UA to BRAF ([Figure 6A](#F0006){ref-type="fig"}), while LEU-21, THR-23, VAL-29, CYS-99, ASP-103, and ILE-165 were responsible for UA binding to ﻿IKKβ ([Figure 6B](#F0006){ref-type="fig"}). For analyzing the binding sites between UA and PLK1, VAL-415, TYR-417, TYR-481, PHE-482, and TYR-485 were involved in stabilizing binding poses ([Figure 6C](#F0006){ref-type="fig"}).Figure 6The views of UA interactions with BRAF (**A**), IKKβ (**B**), and PLK1 (**C**) using iGEMDOCK.**Abbreviations**: UA, ursolic acid; BRAF, B-RAF serine/threonine kinase protein; IKKβ, inhibitor of nuclear factor kappa-B kinase β; PLK1, polo-like kinase 1.

Discussion {#S0004}
==========

Previous studies have demonstrated that ursolic acid has the anti-tumor effect via mediating proliferation, apoptosis, and invasion in types of cancers, such as colorectal cancer,[@CIT0025] liver cancer,[@CIT0026] and squamous skin cancer,[@CIT0027] yet its underlying molecular mechanisms remain unresolved. In the present study, we explored the anti-tumor mechanism and potential targets of using CAMP database.

CMAP has been widely applied to drug discovery and pharmacological research. Tsang-Pai Liu et al identified two novel inhibitors (KM-00927 and BRD-K75081836) of histone deacetylase (HDAC).[@CIT0017] Our CMAP analysis showed that UA and IKK, PLK, and BRAF inhibitors had the obviously positive correlation in gene expression profiles by CMAP. Further data revealed that UA could inhibit PLK1, RAF/ERK, and IKK/NF-κB pathway by Western blot.

RAF/ERK pathway is the most frequently deregulated in cancer and plays a key role in carcinogenesis.[@CIT0028] Paramee et al showed that Kaempferia parviflora inhibits proliferation, migration, and induced apoptosis through down-regulating ERK pathway in ovarian cancer cells.[@CIT0029] *Celastrus orbiculatus* extracts induced apoptosis of gastric adenocarcinoma cell line MGC-803 via mediating ERK1/2.[@CIT0030] Our study showed that UA markedly suppressed the phosphorylation level of BRAF and ERK1/2.

The IKK/NF-κB pathway is also inhibited by UA. NF-κB is widely considered as a key mediator between inflammation and cancer. It regulates the transcriptional activation of genes with anti-apoptosis function, cell proliferation, tumor initiation, and progression, such as cyclin D1, Bcl-2, and so on.[@CIT0031]--[@CIT0034] In the present study, we demonstrated that UA down-regulated the phosphorylation activation of IKKβ and p65, and docking analysis suggests that UA can bind to IKKβ function domain.

PLK1, which phosphorylate a myriad of centrosomal/mitotic protein substrates to insure the fidelity of mitotic progression.[@CIT0035] Donizy et al demonstrated that PLK1 displays an important role in breast progression.[@CIT0036] Zhang and Pati found that Sepin-1, a potent non-competitive inhibitor of separase, inhibits breast cancer cell growth through decreasing phosphorylation levels of RAF, PLK1, and FoxM1.[@CIT0037] The combination of PLK1 inhibitor and tankyrase-1 inhibitor could enhance the anti-cancer effect in triple-negative breast cancer cells.[@CIT0038] This study revealed the anti-BC mechanism of UA through the inhibition of PLK1 phosphorylation level and suggest that UA could interact with PLK1 structure in TYR-485, located in functional domain.

In conclusion, our results demonstrated that UA inhibited BC via modulating PLK1, IKK/NF-κB, and BRAF/ERK pathways. These findings provide a more comprehensive understanding of the mechanism by which UA exerts its anti-tumor effects and support its use in the treatment of breast cancer.
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[^1]: **Abbreviations:** CMAP, connectively map; UA, ursolic acid; NF-κB, nuclear factor kappa-B; RAF, RAF, serine/threonine kinase protein; IKK, inhibitor of nuclear factor kappa-B kinase; PLK, polo-like kinase; PKC, protein kinase C; ATPase, adenosine triphosphate synthase.
